- Home
- AVTX vs PMVP Comparison
AVTX vs PMVP Comparison
Compare AVTX & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- PMVP
- Stock Information
- Founded
- AVTX 2011
- PMVP 2013
- Country
- AVTX United States
- PMVP United States
- Employees
- AVTX N/A
- PMVP N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- AVTX Health Care
- PMVP Health Care
- Exchange
- AVTX Nasdaq
- PMVP Nasdaq
- Market Cap
- AVTX 88.4M
- PMVP 71.9M
- IPO Year
- AVTX 2015
- PMVP 2020
- Fundamental
- Price
- AVTX $7.42
- PMVP $1.24
- Analyst Decision
- AVTX Strong Buy
- PMVP Strong Buy
- Analyst Count
- AVTX 5
- PMVP 3
- Target Price
- AVTX $36.75
- PMVP $5.33
- AVG Volume (30 Days)
- AVTX 102.5K
- PMVP 132.4K
- Earning Date
- AVTX 05-12-2025
- PMVP 03-03-2025
- Dividend Yield
- AVTX N/A
- PMVP N/A
- EPS Growth
- AVTX N/A
- PMVP N/A
- EPS
- AVTX N/A
- PMVP N/A
- Revenue
- AVTX $820,000.00
- PMVP N/A
- Revenue This Year
- AVTX N/A
- PMVP N/A
- Revenue Next Year
- AVTX N/A
- PMVP N/A
- P/E Ratio
- AVTX N/A
- PMVP N/A
- Revenue Growth
- AVTX N/A
- PMVP N/A
- 52 Week Low
- AVTX $4.35
- PMVP $1.20
- 52 Week High
- AVTX $34.46
- PMVP $2.26
- Technical
- Relative Strength Index (RSI)
- AVTX 49.36
- PMVP 36.90
- Support Level
- AVTX $6.38
- PMVP $1.20
- Resistance Level
- AVTX $8.40
- PMVP $1.27
- Average True Range (ATR)
- AVTX 1.11
- PMVP 0.07
- MACD
- AVTX 0.08
- PMVP -0.01
- Stochastic Oscillator
- AVTX 21.93
- PMVP 16.00
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.